About Type 1 Diabetes Drugs

Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:

• Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas does not produce the required amount of insulin in the body, leading to high blood glucose levels.

• Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.

• Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.

Read more at: http://www.researchbeam.com/global-type-1-diabetes-2016-2020-market

Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the body’s ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.

Researchbeam’s analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilar used to treat and prevent type 1 diabetes.

The market is divided into the following segments based on geography:

• Americas

• APAC

• EMEA

Researchbeam's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• Eli Lilly and Company

• Novo Nordisk A/S

• Sanofi SA

Other prominent vendors

• Adocia

• Astellas Pharma

• AstraZeneca

• Baxalta

• BHV Pharma

• Biocon

• Biodel

• Boehringer Ingelheim

• CureDM

• Dance Biopharm

• Diamyd Therapeutics AB

• Diasome Pharmaceuticals

• DiaVac

• Exsulin

• Gan & Lee Pharmaceuticals

• Generex Biotechnology

• GlaxoSmithKline

• ILTOO Pharma

• Intrexon

• Islet Sciences

• Kamada

• Kotobuki Pharmaceutical

• Lexicon Pharmaceuticals

• Living Cell Technologie

• MacroGenics

• MannKind Pharmaceuticals

• Merck

• Merrion Pharmaceutical

• Oramed Pharmaceuticals

• Osiris Therapeutics

• Perle Biosciences

• Pfizer

• REGiMMUNE

• Strongbridge Biopharma

• Toleranzia

• Tolerio

• Xeris Pharmaceuticals

• XOMA

Market driver

• Increase in prevalence of type 1 diabetes

• For a full, detailed list, view our report

Market challenge

• Poor storage conditions and distribution policies for insulin

• For a full, detailed list, view our report

Market trend

• Awareness programs and initiatives

• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?

• What are the key market trends?

• What is driving this market?

• What are the challenges to market growth?

• Who are the key vendors in this market space?

• What are the market opportunities and threats faced by the key vendors?

• What are the strengths and weaknesses of the key vendors?

Request report sample @ http://www.researchbeam.com/global-type-1-diabetes-2016-2020-market/enquire-about-report

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of the report

Market overview

Top-vendors

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction 
Key market highlights 
Key buying criteria 

PART 05: Disease overview 
Introduction 
Risk factors 
Diagnosis 
Management 
Epidemiology 
Economic burden 

PART 06: Insulin: An overview 
Product portfolio 
Global human insulin market 

PART 07: Pipeline analysis 
Faster-acting insulin aspart (NN1218) 
Farxiga/Forxiga 
SAR342434 
NN9211 
LY2605541 
Sotagliflozin 
MK-1293 
PRL001 
Otelixizumab 

About Us:

With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency. With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

Contact Us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
U.S. & Canada Toll Free: + 1-800-910-6452
International: + 1-503-894-6022
UK: + 44-845-528-1300
India: +91 20 66346070
Fax : +1 (855) 550-5975
Email: help@researchbeam.com
Web: http://www.researchbeam.com